Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis

Authors: Cesar Cilento Ponce, Maria de Lourdes F. Chauffaille, Silvia Saiuli M. Ihara, Maria Regina R. Silva

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

The aim of this study was to perform an immunohistochemical analysis from 100 megakaryocytes per sample, analyzing positivity and intensity levels of anti-LAP human TGF-β1 (or Latent TGF-β1) and anti-TGF-β1 (or Active TGF-β1) antibodies from 18 essential thrombocythemia (ET) and 38 primary myelofibrosis (PMF) patients (being 19 pre-fibrotic and 19 fibrotic). Six bone marrow donor biopsies were used as controls. Fibrosis in bone marrow biopsies (BMB) was evaluated according to the European Consensus. The average fibrosis grade differed between each group (P = 0.001 or P = 0.003). Latent TGF-β1 values differed significantly between pre-fibrotic (P = 0.018) and fibrotic (P = 0.031) groups when compared with the control group. The high immunoexpression level of Latent TGF-β1 in the megakaryocytes from patients with myelofibrosis, which was not observed in patients with essential thrombocythemia, may be associated with the development of bone marrow fibrosis.
Literature
1.
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–5.PubMed
2.
Foucar K. Bone Marrow Pathology. 2nd ed. Chicago: ASCP Press (American Society for Clinical Pathology); 2001.
3.
Spivak JL, Siver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112:231–9.PubMedCrossRef
4.
Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413–37.PubMedCrossRef
5.
Thiele J, Kvanicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.PubMed
6.
Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythaemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.PubMedCrossRef
7.
Kuter D, Bain B, Mufti G, Bagg A, Hasserjian R. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139:351–62.PubMedCrossRef
8.
Sporn MB, Roberts AB. Transforming growth factor-beta: recent progress and new challenges. J Cell Biol. 1992;119(5):1017–21.PubMedCrossRef
9.
Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8.PubMedCrossRef
10.
Hyytiäinen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci. 2004;41:233–64.PubMedCrossRef
11.
Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Valdwin AK, McGovern A, Baldock C, Shuttleworth A, Kielty CM. Assembly of fibrillin microfibrils governs extracellular deposition of Latent TGF β. J Cell Sci. 2010;123:3006–18.PubMedCrossRef
12.
Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin -1mechanisms and physiology. Cytokine & Growth Factor Rev. 2000;11:59–69.CrossRef
13.
Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF beta activation. J Cell Sci. 2003;116(Pt 2):217–24.PubMedCrossRef
14.
de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytoquine Growth Factor Rev. 2004;15(1):1–11.CrossRef
15.
Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor β 1 has a longer plasma half-life in rats than active transforming growth factor β 1, and a different tissue distribution. J Clin Investig. 1990;86:1976–84.PubMedCrossRef
16.
Vaughan JM, Vale WW. α2-Macroglobulin is a binding protein of inhibin and activin. Endocrinology. 1993;132:2038–50.PubMedCrossRef
17.
Thiele J, Hoeppner B, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/sclerosis (agnogenic myeloid metaplasia)—correlations between clinical and morphological features. Virchows Arch A Pathol Anat Histopathol. 1989;415(3):191–202.PubMedCrossRef
18.
Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3):986–93.PubMedCrossRef
19.
Dong M, Blobe GC. Role of transforming growth factor-β in hematologic malignancies. Blood. 2006;107(12):4589–96.PubMedCrossRef
20.
Bain BJ, Clark DM, Lampert IA, Wilkins BS. Bone marrow pathology. London: Blackwell; 2001.CrossRef
21.
Gomori G. Silver impregnation of reticulum in paraffin sections. Am J Pathol. 1937;13:993–1001.PubMed
22.
Gomori G. The effect of certain factors on the results of silver impregnation for reticulum fibers. Am J Pathol. 1939;15:493–5.PubMed
23.
van der Woude CJ, Kleibeuker JH, Tiebosch ATGM, Homan M, Beuving A, Jansen PLM, Moshage HJ. Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. J Clin Pathol. 2003;56:699–702.PubMedCrossRef
24.
Ponce CC, Chauffaille MLF, Ihara SSM, Silva MRR. MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis. Leuk Res. 2012;36(1):93–7.PubMedCrossRef
25.
Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad 4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor—beta 1. Br J Haematol. 2004;124:211–20.PubMedCrossRef
26.
Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–503.PubMedCrossRef
27.
Bock O, Loch G, Schade U, Wasielewski von R, Schlué J, Kreipe H. Aberrant expression of transforming growth factor B-1 (TGFB-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol. 2005;205:548–57.PubMedCrossRef
28.
Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor beta, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol. 2000;104(4):151–7.PubMedCrossRef
29.
Taipale J, Saharinen J, Hedman K, Keski-Oja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrilschem. J Histo Cytochem. 1996;44:875–89.CrossRef
30.
Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, Mosher DF, Humphries MJ, Kielty CM. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem. 2005;280:18871–80.PubMedCrossRef
Metadata
Title
The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis
Authors
Cesar Cilento Ponce
Maria de Lourdes F. Chauffaille
Silvia Saiuli M. Ihara
Maria Regina R. Silva
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0144-1

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue

Original Paper

Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β

Original Paper

Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia

Original Paper

Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor

Short Communication

A new dic(7;12)(p12.21;p12.2) and i(12)(q10) during the lymphoid blast crisis of patient with Ph+ chronic myeloid leukemia

Original Paper

Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China

Case Report

Three different KRAS statuses in three synchronous colorectal cancers
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits